|
1
|
Barlogie B, Shaughnessy J, Tricot G,
Jacobson J, Zangari M, Anaissie E, Walker R and Crowley J:
Treatment of multiple myeloma. Blood. 103:20–32. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anderson KC: Therapeutic advances in
relapsed or refractory multiple myeloma. J Natl Compr Canc Netw 11
(Suppl 5). 676–679. 2013.
|
|
3
|
Accardi F, Toscani D, Bolzoni M, Palma B
Dalla, Aversa F and Giuliani N: Mechanism of action of bortezomib
and the new proteasome inhibitors on myeloma cells and the bone
microenvironment: impact on myeloma-induced alterations of bone
remodeling. BioMed Res Int. 2015:1724582015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adam Z, Sčudla V, Krejčí M, Cermáková Z,
Pour L and Král Z: Treatment of AL amyloidosis in 2012; the benefit
of new drugs (bortezomib, thalidomide, and lenalidomide). Summary
of published clinical trials. Vnitr Lek. 59:37–58. 2013.(In Czech).
PubMed/NCBI
|
|
5
|
Adachi Y, Yoshio-Hoshino N and Nishimoto
N: Gene therapy for multiple myeloma. Curr Gene Ther. 8:247–255.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tétreault N and De Guire V: miRNAs: Their
discovery, biogenesis and mechanism of action. Clin Biochem.
46:842–845. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Parker JS, Roe SM and Barford D: Molecular
mechanism of target RNA transcript recognition by Argonaute-guide
complexes. Cold Spring Harb Symp Quant Biol. 71:45–50. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abe M: Multiple myeloma. Nihon Rinsho.
67:991–995. 2009.(In Japanese). PubMed/NCBI
|
|
9
|
Abdi J, Chen G and Chang H: Drug
resistance in multiple myeloma: Latest findings and new concepts on
molecular mechanisms. Oncotarget. 4:2186–2207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abidi MH, Gul Z, Abrams J, Ayash L, Deol
A, Ventimiglia M, Lum L, Mellon-Reppen S, Al-Kadhimi Z,
Ratanatharathorn V, et al: Phase I trial of bortezomib during
maintenance phase after high dose melphalan and autologous stem
cell transplantation in patients with multiple myeloma. J
Chemother. 24:167–172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Abba M, Mudduluru G and Allgayer H:
MicroRNAs in cancer: Small molecules, big chances. Anticancer
Agents Med Chem. 12:733–743. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Azmi AS, Bao B and Sarkar FH: Exosomes in
cancer development, metastasis, and drug resistance: A
comprehensive review. Cancer Metastasis Rev. 32:623–642. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Allen KE and Weiss GJ: Resistance may not
be futile: microRNA biomarkers for chemoresistance and potential
therapeutics. Mol Cancer Ther. 9:3126–3136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Akao Y, Khoo F, Kumazaki M, Shinohara H,
Miki K and Yamada N: Extracellular disposal of tumor-suppressor
miRs-145 and −34a via microvesicles and 5-FU resistance of human
colon cancer cells. Int J Mol Sci. 15:1392–1401. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bai H, Xu R, Cao Z, Wei D and Wang C:
Involvement of miR-21 in resistance to daunorubicin by regulating
PTEN expression in the leukaemia K562 cell line. FEBS Lett.
585:402–408. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bai WD, Ye XM, Zhang MY, Zhu HY, Xi WJ,
Huang X, Zhao J, Gu B, Zheng GX, Yang AG, et al: MiR-200c
suppresses TGF-β signaling and counteracts trastuzumab resistance
and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int J
Cancer. 135:1356–1368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fu D, Liu B, Zang LE and Jiang H:
MiR-631/ZAP70: A novel axis in the migration and invasion of
prostate cancer cells. Biochem Biophys Res Commun. 469:345–351.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Eldridge AG and O'Brien T: Therapeutic
strategies within the ubiquitin proteasome system. Cell Death
Differ. 17:4–13. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Okamoto Y, Ozaki T, Miyazaki K, Aoyama M,
Miyazaki M and Nakagawara A: UbcH10 is the cancer-related E2
ubiquitin-conjugating enzyme. Cancer Res. 63:4167–4173.
2003.PubMed/NCBI
|
|
20
|
Lin J, Raoof DA, Wang Z, Lin MY, Thomas
DG, Greenson JK, Giordano TJ, Orringer MB, Chang AC, Beer DG, et
al: Expression and effect of inhibition of the
ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma.
Neoplasia. 8:1062–1071. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Troncone G, Guerriero E, Pallante P,
Berlingieri MT, Ferraro A, Del Vecchio L, Gorrese M, Mariotti E,
Iaccarino A, Palmieri EA, et al: UbcH10 expression in human
lymphomas. Histopathology. 54:731–740. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Berlingieri MT, Pallante P, Sboner A,
Barbareschi M, Bianco M, Ferraro A, Mansueto G, Borbone E,
Guerriero E, Troncone G, et al: UbcH10 is overexpressed in
malignant breast carcinomas. Eur J Cancer. 43:2729–2735. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Berlingieri MT, Pallante P, Guida M, Nappi
C, Masciullo V, Scambia G, Ferraro A, Leone V, Sboner A,
Barbareschi M, et al: UbcH10 expression may be a useful tool in the
prognosis of ovarian carcinomas. Oncogene. 26:2136–2140. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao L, Jiang L, Wang L, He J, Yu H, Sun
G, Chen J, Xiu Q and Li B: UbcH10 expression provides a useful tool
for the prognosis and treatment of non-small cell lung cancer. J
Cancer Res Clin Oncol. 138:1951–1961. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang C, Pan YH, Shan M, Xu M, Bao JL and
Zhao LM: Knockdown of UbcH10 enhances the chemosensitivity of dual
drug resistant breast cancer cells to epirubicin and docetaxel. Int
J Mol Sci. 16:4698–4712. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Doherty FJ, Dawson S and Mayer RJ: The
ubiquitin-proteasome pathway of intracellular proteolysis. Essays
Biochem. 38:51–63. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Summers MK, Pan B, Mukhyala K and Jackson
PK: The unique N terminus of the UbcH10 E2 enzyme controls the
threshold for APC activation and enhances checkpoint regulation of
the APC. Mol Cell. 31:544–556. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stieglitz B, Rana RR, Koliopoulos MG,
Morris-Davies AC, Schaeffer V, Christodoulou E, Howell S, Brown NR,
Dikic I and Rittinger K: Structural basis for ligase-specific
conjugation of linear ubiquitin chains by HOIP. Nature.
503:422–426. 2013. View Article : Google Scholar : PubMed/NCBI
|
